Halozyme Therapeutics (HALO) Enterprise Value (2016 - 2025)
Halozyme Therapeutics (HALO) has disclosed Enterprise Value for 16 consecutive years, with -$142.8 million as the latest value for Q4 2025.
- On a quarterly basis, Enterprise Value rose 76.04% to -$142.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$142.8 million, a 76.04% increase, with the full-year FY2025 number at -$142.8 million, up 76.04% from a year prior.
- Enterprise Value was -$142.8 million for Q4 2025 at Halozyme Therapeutics, up from -$702.0 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$118.4 million in Q3 2022 to a low of -$747.9 million in Q1 2025.
- A 5-year average of -$419.9 million and a median of -$343.3 million in 2023 define the central range for Enterprise Value.
- Peak YoY movement for Enterprise Value: tumbled 152.33% in 2022, then skyrocketed 76.04% in 2025.
- Halozyme Therapeutics' Enterprise Value stood at -$740.9 million in 2021, then skyrocketed by 51.03% to -$362.8 million in 2022, then rose by 7.39% to -$336.0 million in 2023, then tumbled by 77.4% to -$596.1 million in 2024, then surged by 76.04% to -$142.8 million in 2025.
- Per Business Quant, the three most recent readings for HALO's Enterprise Value are -$142.8 million (Q4 2025), -$702.0 million (Q3 2025), and -$747.9 million (Q1 2025).